REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study
Radiation Oncology · 2024
DOI: 10.1186/s13014-024-02445-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Giuditta Chiloiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario Agostino Gemelli, IRCSS, Rome, Italy. Hauptthemen laut MEDLINE: Radiosurgery, Radiotherapy, Image-Guided, Liver Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Oligo-progression or further recurrence is an open issue in the multi-integrated management of oligometastatic disease (OMD). Re-irradiation with stereotactic body radiotherapy (re-SBRT) technique could represent a valuable treatment option to improve OMD clinical outcomes. MRI-guided allows real-time visualization of the target volumes and online adaptive radiotherapy (oART). The aim of this retrospective study is to evaluate the efficacy and toxicity profile of MRI-guided repeated SBRT (MRIg-reSBRT) in the OMD setting and propose a re-SBRT classification.
Methods
We retrospectively analyzed patients (pts) with recurrent liver metastases or abdominal metastatic lesions between 1 and 5 centimeters from liver candidate to MRIg-reSBRT showing geometric overlap between the different SBRT courses and assessing whether they were in field (type 1) or not (type 2).
Results
Eighteen pts completed MRIg-reSBRT course for 25 metastatic hepatic/perihepatic lesions from July 2019 to January 2020. A total of 20 SBRT courses: 15 Type 1 re-SBRT (75%) and 5 Type 2 re-SBRT (25%) was delivered. Mean interval between the first SBRT and MRIg-reSBRT was 8,6 months. Mean prescribed dose for the first treatment was 43 Gy (range 24–50 Gy, mean BED α/β10 =93), while 41 Gy (range 16–50 Gy, mean BED α/β10 =92) for MRIg-reSBRT. Average liver dose was 3,9 Gy (range 1–10 Gy) and 3,7 Gy (range 1,6–8 Gy) for the first SBRT and MRIg-reSBRT, respectively. No acute or late toxicities were reported at a median follow-up of 10,7 months. The 1-year OS and PFS was 73,08% and 50%, respectively. Overall Clinical Benefit was 54%.
Conclusions
MRIg-reSBRT could be considered an effective and safe option in the multi-integrated treatment of OMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario Agostino Gemelli, IRCSS, Rome, Italy.
- Fondazione Policlinico Universitario Agostino Gemelli, IRCSS, Rome, Italy. giulia.panza@guest.policlinicogemelli.it.
- Università Cattolica del Sacro Cuore, Rome, Italy.
Zitieren
APA
Chiloiro, G., Panza, G., Boldrini, L., Romano, A., Placidi, L., Nardini, M., Galetto, M., Votta, C., Campitelli, M., Cellini, F., Massaccesi, M., & Gambacorta, M. A. (2024). REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study. Radiation Oncology. https://doi.org/10.1186/s13014-024-02445-2
Vancouver
Chiloiro G, Panza G, Boldrini L, Romano A, Placidi L, Nardini M, et al. REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study. Radiation Oncology. 2024. doi:10.1186/s13014-024-02445-2
BibTeX
@article{Chiloiro2024,
author = {Chiloiro, Giuditta and Panza, Giulia and Boldrini, Luca and Romano, Angela and Placidi, Lorenzo and Nardini, Matteo and Galetto, Matteo and Votta, Claudio and Campitelli, Maura and Cellini, Francesco and Massaccesi, Mariangela and Gambacorta, Maria Antonietta},
title = {REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study},
journal = {Radiation Oncology},
year = {2024},
doi = {10.1186/s13014-024-02445-2}
}
EUVIMED